Prologue

Drug Safety

Volumn 21, Issue SUPPL. 1, 1999, Pages 1-3

  Roberts, D J ^a  

^a Almirall Prodesfarma SA ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CAREBASTINE; EBASTINE; FEXOFENADINE; POTASSIUM CHANNEL; TERFENADINE;

CONFERENCE PAPER; DRUG LEGISLATION; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TORSADE DES POINTES; VISUAL DISORDER;

EID: 0033429598     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921001-00001     Document Type: Conference Paper

References (24)

1. 1. H.H. Dale 1929 Croonian lectures on some chemical factors in the control of the circulation Lancet I 1179 Dale HH. Croonian lectures on some chemical factors in the control of the circulation. Lancet 1929; I: 1179, 1233, 1285
2. 2. D.J. Roberts 1992 Fifty years of antihistamine research from phenbenzamine (RP 2339) to ebastine (RP 64305) Drugs Today 28 Suppl. B 1 9 Roberts DJ. Fifty years of antihistamine research from phenbenzamine (RP 2339) to ebastine (RP 64305). Drugs Today 1992: 28 Suppl. B: 1–9
3. 3. J.K. Woodward N.L. Munro 1982 Terfenadine, the first non-sedating antihistamine Arzneimittelforschung 32 1154 6 6129860 1:CAS:528:DyaL38XmtVOmt7g%3D Woodward JK, Munro NL. Terfenadine, the first non-sedating antihistamine. Arzneimittelforschung 1982; 32: 1154–6
4. 4. F.H.L. Awouters C.J.E. Niemegeers P.A.J. Janssen 1983 Pharmacology of the specific histamine H 1-antagonist astemizole Arzneimittelforschung 33 381 8 6135428 1:CAS:528:DyaL3sXhslagtrg%3D Awouters FHL, Niemegeers CJE, Janssen PAJ. Pharmacology of the specific histamine H 1-antagonist astemizole. Arzneimittelforschung 1983; 33: 381–8
5. 5. R.L. Woosley 1996 Cardiac actions of antihistamines Ann Rev Pharmacol Toxicol 36 232 52 Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 232–52
6. 6. R.L. Woosley Y. Chen J.P. Freiman 1993 Mechanism of the cardiotoxic actions of terfenadine JAMA 269 1532 6 8445816 10.1001/jama.1993.03500120070028 1:STN:280:DyaK3s7ovVartw%3D%3D Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6
7. 7. M.M. Adamantidis P. Keriam B.A. Dupuis 1994 In vitro electrophysiological detection of iatrogenic arrhythmogenicity Fundam Clin Pharmacol 8 391 407 7875633 10.1111/j.1472-8206.1994.tb00818.x 1:STN:280:DyaK2M7otVOltA%3D%3D Adamantidis MM, Keriam P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8: 391–407
8. 8. D. Rampe B. Wible B. Brown 1993 Effects of terfenadine and its metabolites on a delayed rectifier K + channel cloned from human heart Mol Pharmacol 44 181 90 Rampe D, Wible B, Brown B, et al. Effects of terfenadine and its metabolites on a delayed rectifier K + channel cloned from human heart. Mol Pharmacol 1993; 44: 181–90
9. 9. J.A. Hey 1995 Antihistamine activity, central nervous system and cardiovascular profiles of histamine H 1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs Clin Exp Allergy 25 974 84 8556569 10.1111/j.1365-2222.1995.tb00400.x 1:STN:280:DyaK287itVOqsw%3D%3D Hey JA. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H 1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs. Clin Exp Allergy 1995; 25: 974–84
10. 10. Mastey V. Torsades de pointes in patients receiving terfenadine or astemizole [online]. Drugs and Devices Information Line, Harvard School of Public Health, 1995. Available from: http://www.hsph.harvard.edu/organizations/DDIL/torsades.html (Accessed 1999 Apr 23)
11. 11. Cruzan SM. FDA proposes to withdraw Seldane approval [online]. FDA Talk Paper 1997. Available from: http://www.fda.gov/bbs/topics/ANSWERS/ANS00780.html (Accessed 1999 Apr 23)
12. 12. The European Agency for the Evaluation of Medicinal Products. Final opinion of the Committee for Proprietary Medicinal Products pursuant to article 12 of Council Directive 75/319/EEC as amended for terfenadine containing products. 1997, Feb 25: London; CPMP/255/98-EN
13. 13. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997, Mar (draft) Dec: London; CPMP/986/96
14. 14. J. Moragues D.J. Roberts 1990 Ebastine Drugs Future 15 674 9 Moragues J, Roberts DJ. Ebastine. Drugs Future 1990; 15: 674–9
15. 15. B. Dupuis C. Libersa J. Caron 1995 Electrophysiological effects of ebastine and carebastine on rabbit Purkinje fibres Rhône-Poulenc Rorer US Dupuis B, Libersa C, Caron J, et al. Electrophysiological effects of ebastine and carebastine on rabbit Purkinje fibres. US: Rhône-Poulenc Rorer, 1995 (Data on file)
16. 16. J. Kulp M. Gillen H. Pentikis 1996 A randomized, blinded, four-way crossover, electrocardiographic study of ebastine 60 mg/day and ebastine 100 mg/day compared to terfenadine 360 mg/day, and ebastine placebo in healthy adult male volunteers Rhône-Poulenc Rorer US Kulp J, Gillen M, Pentikis H, et al. A randomized, blinded, four-way crossover, electrocardiographic study of ebastine 60 mg/day and ebastine 100 mg/day compared to terfenadine 360 mg/day, and ebastine placebo in healthy adult male volunteers. US: Rhône-Poulenc Rorer, 1996: Study 136 (Data on file)
17. 17. J. Kulp M. Gillen H. Pentikis 1996 A randomized, blinded, parallel group, multiple dose, placebo controlled ebastine-ketoconazole interaction cardiac safety study in healthy adult male volunteers Rhône-Poulenc Rorer US Kulp J, Gillen M, Pentikis H, et al. A randomized, blinded, parallel group, multiple dose, placebo controlled ebastine-ketoconazole interaction cardiac safety study in healthy adult male volunteers. US: Rhône-Poulenc Rorer, 1996: Study 137 (Data on file)
18. 18. R. Pyke J. Kulp H. Pentikis 1996 A pharmacokinetic and electrocardiographic evaluation of the interaction between multiple doses of ebastine and erythromycin in healthy adult male volunteers Rhône-Poulenc Rorer US Pyke R, Kulp J, Pentikis H, et al. A pharmacokinetic and electrocardiographic evaluation of the interaction between multiple doses of ebastine and erythromycin in healthy adult male volunteers. US: Rhône-Poulenc Rorer, 1996: Study 138 (Data on file)
19. 19. J. Gras J. Llenas J.M. Palacios 1996 Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTc interval Eur J Allergy Clin Immunol 31 51 155 Gras J, Llenas J, Palacios JM. Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTc interval. Eur J Allergy Clin Immunol 1996; 31(51): 155
20. 20. Hey JA. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996: 153-8
21. 21. Hey JA. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittelforschung 1996: 159-63
22. 22. J. Gras J. Llenas J.M. Palacios 1996 The role of ketoconazole in the QTc interval prolonging effects of H 1-antihistamines in a guinea-pig model of arrhythmogenicity Br J Pharmacol 119 187 8 8886395 10.1111/j.1476-5381.1996.tb15968.x 1:CAS:528:DyaK28XmtFSjurc%3D Gras J, Llenas J, Palacios JM, et al. The role of ketoconazole in the QTc interval prolonging effects of H 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119: 187–8
23. 23. A. Williams W.S. Redfern A. Day 1996 Prolongation of QTc interval by ketoconazole in conscious guinea-pigs implanted with ECG telemetry transducers Br J Pharmacol 119 356P Williams A, Redfern WS, Day A, et al. Prolongation of QTc interval by ketoconazole in conscious guinea-pigs implanted with ECG telemetry transducers. Br J Pharmacol 1996; 119: 356P
24. 24. D.J. Roberts J. Llenas 1996 Second generation antihistamines and cardiotoxicity. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig [discussion] Arzneimittelforschung 46 832 3 9125289 1:CAS:528:DyaK28XltVyrtbs%3D Roberts DJ, Llenas J. Second generation antihistamines and cardiotoxicity. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig [discussion]. Arzneimittelforschung 1996; 46: 832–3